Montes de Oca MB, Saviñón TJA

Language: Spanish
References: 16
Page: 25-27
PDF size: 50.43 Kb.

ABSTRACT

The medical literature shows an enormous quantity of comparative studies between generics and brand name medications. The medical field directly related with this area is pharmacology and the applied area clinical pharmacology. Recently an article was published where pharma-cologists try to teach medical doctors about both kinds of medication. A good knowledge of the pharmacokinetic principles is essential in order to appropriately prescribe drugs the same way pharmacodynamics principles prove its efficacy. This presentation will provide basic orientation to medical doctors especially psychiatrists over pharmacokinetics and the principles that govern prescription of medications in general. A special attention will be placed to bioequivalences between drugs and the procedures followed by experienced countries on this issue. Controversies, real cases, and several studies will be used as examples to clarify the concept of generic drugs and the pharmaceutical labs responsible for the products. The only objetive of this work we present is education in order to be able to use in a more efficient way the generic products and a suggestion for some strategies to identify defective generic drugs.

REFERENCES

1. Janicak PG, Davis JM, Preskorn SH, Ayd FJ Jr. Principles and practice of Psychopharmacotherapy. 1997; 3: 70-1.

2. Janicak PG, Davis JM, Preskorn SH, Ayd FJ Jr. Principles and practice of Psychopharmacotherapy. 1997; 3: 69-70.

3. Janicak PG, Davis JM, Preskorn SH, Ayd FJ Jr. Principles and practice of Psychopharmacotherapy. 1997; 3: 61.

4. Janicak PG, Davis JM, Preskorn SH, Ayd FJ Jr. Principles and practice of Psychopharmacotherapy. 1997; 3: 69-77.

5. Goonetilleke AK, Munasingha JM, Gurude DS, Samaraweera DS. Plasma pharmacokinetics of a generic amoxycillin and the innovator brand: a comparison. Ceylon Med J 1998; 43 (1): 16-8.

6. Oles KS, Penry JK, Smith LD, Anderson RL. Therapeutic bioequivalency study of brand name versus generic carbamazepine. Neurology 1992; 42 (6): 1147-53.

7. Schatzberg AF, Cole JO, Debattista C. Manual of clinical psychopharmacology. 1997; 1: 9-10.

8. Doering PL, Araujo OE, Flowers FP. J Am Acad Dermatol 1987; 16 (5-1): 1068-70.

9. Urbanek K, Varekova P. A modeling analysis of possible generic substitutions in an impatient facility. Ceska Slov Farm 1997; 46 (2): 74-7.0

10. Munio S. A vision of the pharmaceutical industry. Methods Find Exp Clin Pharmacol 1998; 20 Suppl A: 5-9 Novartis Pharma S.A., Barcelona, Spain.

11. Vallee JP. Generic drugs and the rights of substitution. Presse Med 1999; 28 (10): 535-8.

12. Olsen EA. A double-blind controlled comparison of generic and trade name topical steroids using vasoconstriction assay. Arch Dermatol 127 (2): 197-201.

13. Stoffer SS, Szpunar WE. Potency of brand name and generic levothyroxine. Jama 1980; 244 (15): 1704-5.

14. Pincus RC. Brand name, generic prescribing, and generic substitution. Med J Australia 1983; 2 (2): 89-91.

15. Joly P. Responsabilities and generic drugs. Bull Acad Natl Med 1996; 180 (2): 463-73.

16. Mikati M, Bassett N, Schachter S. Double-blind randomized study comparing brand name and generic phenytoin monotherapy. Epilepsia 1992; 33 (2): 359-65.